期刊
COLLOIDS AND SURFACES B-BIOINTERFACES
卷 117, 期 -, 页码 346-353出版社
ELSEVIER
DOI: 10.1016/j.colsurfb.2014.02.051
关键词
Electrospray; Nanotechnology; Controlled release; Drug delivery; Biomaterials
资金
- National Taiwan University of Science and Technology
- National Science Council of Taiwan [NSC-101-2221-E-011-053-, NSC-102-2221-E-011-070-]
Cisplatin-encapsulating maleimide-polyethylene glycol-Poly(D,L-lactic-co-glycolide) (cis-encapsulating mal-PEG-PLGA) particles were produced using the electrospray technique and bioconjugated with CD44 monoclonal antibody, targeting the counterpart receptor. The produced suspension of cis-encapsulating CD44-PEG-PLGA particles contains an antibody loading of 12.65-15.17 mu g/mL and efficiently targets a CD44-overexpressed ovarian cancer cell line, such as CP70 and SKOV-3, within 6 h of treatment, which was determined by Bradford assay, immunofluorescence analysis, and confocal laser scanning microscopic (CLSM) study. Most importantly, no tedious multi-step bioconjugation procedures are needed to synthesize mal-PEG-PLGA vehicles for antibody and drug loading, avoiding the undesirable hydrolysis of mal-PEG moiety and so successfully generating the cis-encapsulating mal-PEG-PLGA particles within one step. After conjugation of the CD44 antibody, the produced cis-encapsulating CD44-PEG-PLGA particles exhibited a better anti-proliferative ability against ovarian cancer cells compared to free form of cisplatin and PLGA particles without CD44 conjugation. Notably, the cis-encapsulating CD44-PEG-PLGA particles have approximately 10-14% greater the anti-proliferative ability against CP70 and SKOV-3 cells at a concentration of 1.25 mu M, which falls within the concentrations used in chemotherapy. The proposed antibody-functionalization strategy represents an excellent platform for preparing particles with targeting ability in cancer therapy in vitro or in vivo. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据